Dr. Munden earned his D.M.D. in 1982 and his M.D. in 1990 from the Medical University of South Carolina in Charleston. After dental school, he was in private practice for 3 years and served as an assistant professor of dentistry at the Medical University of South Carolina Dental School for 3 years. After medical school, he remained in Charleston for his residency in Diagnostic Radiology. In 1994, Dr. Munden moved to Boston where he completed a Fellowship in Thoracic Radiology. 

Dr. Munden is a member of and serves in leadership positions in a number of national and international radiology organizations, including the World Congress of Thoracic Imaging, Society of Thoracic Radiology, Radiological Society of North America (RSNA), American Roentgen Ray Society, American College of Radiology (ACR), American College of Radiology Imaging Network (ACRIN), and the Radiation Therapy Oncology Group. Currently, he serves as Chair of Chest Scientific Committee of the RSNA, and is a member of the ACRIN Executive Committee of the National Lung Screening Trial and the ACR Practice Guidelines for CT Screening of Lung Cancer.

Dr. Munden has been extensively involved in evaluating the role of imaging (including chest radiographs, CT, and PET/CT) in lung cancer and other thoracic malignancies. He has extensive experience in the application and translation of imaging research for evaluating lung cancer, esophageal cancer, and other thoracic malignancies. He has a special interest in assessing the tumor response to therapy and lung cancer screening. He has participated in over 40 clinical trials and served as the National Lung Screening Trial (NLST) site PI for the MD Anderson Cancer Center (MDACC). This site participated in targeted recruitment of underrepresented populations for the NLST and has significant experience in recruitment for lung cancer screening. His interest in screening continues with further evaluation and publication of NLST data, development of recommendations and guidelines for lung cancer screening, and biomarker utilization for screening and assessing the value of lung cancer screening.